{"disease":{"id":"myxoid-liposarcoma","name":"myxoid liposarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02180867","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02609984","title":"Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02106312","title":"Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT05836571","title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT06748872","title":"EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Medigene AG","has_results":false},{"nct_id":"NCT01532687","title":"Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT06843967","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04044768","title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"USWM CT, LLC","has_results":true},{"nct_id":"NCT06083883","title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03989596","title":"Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Maria Sklodowska-Curie National Research Institute of Oncology","has_results":false},{"nct_id":"NCT03063632","title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03670069","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06414434","title":"BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Michael Wagner, MD","has_results":false},{"nct_id":"NCT03450122","title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05492682","title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Valo Therapeutics Oy","has_results":false},{"nct_id":"NCT04794127","title":"Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT01957709","title":"Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT07261657","title":"N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03399448","title":"NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03397186","title":"Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06617572","title":"Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"USWM CT, LLC","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}